Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ALXO

Alx Oncology Holdings Inc

Dec 12 • 11:30AM ET

1.57

Dollar change +0.06
Percentage change 3.91	%

Healthcare • Biotechnology • USA • NASD

Peers: IOVA KPTI SRRK XNCR CARA AFMD TGTX BHVN ZLAB BPMC

| Held by: IWM VTI VXF IWO IBB SCHA VTWO IWC VHT ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.98	Insider Own	34.96%	Shs Outstand	52.74M	Perf Week	-13.31%
Market Cap	82.76M	Forward P/E	-	EPS next Y	-2.50	Insider Trans	0.00%	Shs Float	34.30M	Perf Month	17.10%
Income	-151.16M	PEG	-	EPS next Q	-0.67	Inst Own	58.48%	Short Float	20.91%	Perf Quarter	-29.32%
Sales	0.00M	P/S	-	EPS this Y	26.31%	Inst Trans	-24.59%	Short Ratio	9.52	Perf Half Y	-81.41%
Book/sh	2.59	P/B	0.60	EPS next Y	9.14%	ROA	-74.50%	Short Interest	7.17M	Perf Year	-87.75%
Cash/sh	2.82	P/C	0.56	EPS next 5Y	-	ROE	-98.94%	52W Range	1.19 - 17.83	Perf YTD	-89.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-50.98%	ROI	-99.25%	52W High	-91.20%	Beta	1.04
Dividend TTM	-	Quick Ratio	4.82	Sales past 5Y	-8.67%	Gross Margin	-	52W Low	31.86%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	4.82	EPS Y/Y TTM	16.43%	Oper. Margin	-	RSI (14)	51.62	Volatility	11.36% 9.62%
Employees	72	Debt/Eq	0.13	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.57	Target Price	10.40
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	52.98%	Payout	-	Rel Volume	2.24	Prev Close	1.51
Sales Surprise	-	EPS Surprise	25.64%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	753.20K	Price	1.57
SMA20	6.35%	SMA50	4.92%	SMA200	-76.93%	Trades		Volume	577,032	Change	3.91%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-08-24	Downgrade	Stifel	Buy → Hold	$10 → $14
Dec-08-23	Upgrade	Jefferies	Hold → Buy	$8 → $18
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$65 → $25
Sep-30-21	Initiated	Stifel	Buy	$106
May-05-21	Resumed	Credit Suisse	Outperform	$98
Apr-26-21	Resumed	Credit Suisse	Outperform	$98
Apr-06-21	Initiated	UBS	Buy
Feb-10-21	Initiated	H.C. Wainwright	Buy	$100
Aug-11-20	Initiated	Piper Sandler	Overweight	$55
Aug-11-20	Initiated	Jefferies	Buy	$50
Aug-11-20	Initiated	Credit Suisse	Outperform	$53
Aug-11-20	Initiated	Cantor Fitzgerald	Overweight	$64

Show Previous Ratings

Today 08:00AM	ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 (GlobeNewswire)
Dec-10-24 09:00AM	ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer (GlobeNewswire) -8.14%
Nov-26-24 08:00AM	ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-21-24 09:35AM	ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +6.61%
Nov-14-24 08:00AM	ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer (GlobeNewswire)
04:00PM	Loading…
Nov-07-24 04:00PM	ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-24 08:00AM	ALX Oncology Announces November Investor Conference Participation (GlobeNewswire)
Nov-01-24 05:30PM	ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 (GlobeNewswire)
Oct-10-24 07:04PM	Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc (GuruFocus.com) -11.11% +6.94%
Sep-09-24 08:00AM	ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) +9.95%
Sep-04-24 08:00AM	ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi (GlobeNewswire)
Aug-08-24 04:05PM	ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-06-24 04:01PM	ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors (GlobeNewswire) -6.55%
Aug-01-24 09:05AM	Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients (Benzinga) -41.67%
06:52AM	ALX Oncologys evorpacept shows potential in Phase II gastric cancer trial (Clinical Trials Arena)
04:01PM	Loading…
Jul-31-24 04:01PM	ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer (GlobeNewswire) -11.93%
05:30AM	ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Jun-17-24 11:00AM	Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO) (GuruFocus.com) -8.32%
Jun-03-24 09:35AM	Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround (Zacks) -15.71%
Jun-02-24 10:00AM	ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer (GlobeNewswire)
May-29-24 09:00AM	ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference (GlobeNewswire) -10.91%
May-16-24 02:54AM	Insider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells Shares (GuruFocus.com)
May-14-24 09:55AM	Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet (Zacks)
May-10-24 02:21PM	ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ... (GuruFocus.com)
May-09-24 10:57PM	ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024 (InvestorPlace)
04:00PM	ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 05:38PM	Alx Oncology Holdings Insider Sold Shares Worth $318,334, According to a Recent SEC Filing (MT Newswires) -5.41%
May-07-24 09:00AM	ALX Oncology Appoints Allison Dillon as Chief Business Officer (GlobeNewswire) +11.28%
Apr-30-24 09:00AM	ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer (GlobeNewswire)
Apr-24-24 10:00AM	ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting (GlobeNewswire)
09:30AM	Loading…
Apr-11-24 09:30AM	ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study (Zacks) +11.04%
Apr-09-24 05:30PM	ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma ( R/R B-NHL ) (GlobeNewswire)
Apr-06-24 01:33AM	ALX Oncology Holdings Inc (ALXO) Insider Sells Shares (GuruFocus.com)
Mar-08-24 03:48PM	ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer (Benzinga) -6.34%
Mar-07-24 10:53PM	ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q4 2023 (InvestorPlace) +9.95%
10:41PM	ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending (GuruFocus.com)
04:03PM	ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 04:30PM	ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting (GlobeNewswire)
Jan-03-24 08:00AM	ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-23 04:21PM	7 Small-Cap Stocks That Wall Street Loves for Good Reason (InvestorPlace) +18.04%
Nov-13-23 04:47PM	ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com) +8.08%
04:05PM	ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-23 04:05PM	ALX Oncology Announces November Investor Conference Participation (GlobeNewswire) +6.35%
Oct-10-23 04:05PM	ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +16.24%
Oct-06-23 04:59AM	The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna (Zacks) +27.38%
Oct-05-23 10:58AM	Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More (Zacks)
08:00AM	ALX Oncology Announces Pricing of Public Offering (GlobeNewswire)
Oct-04-23 04:10PM	ALX Oncology Announces Proposed Public Offering (GlobeNewswire) -15.05%
11:39AM	ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data (Zacks)
Oct-03-23 11:15AM	Why ALX Oncology Stock Is Skyrocketing Today (Motley Fool) +56.13%
09:36AM	Midday movers: McCormick Airbnb, Point Biopharma and more (Investing.com)
06:00AM	ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Oct-02-23 04:05PM	ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer (GlobeNewswire)
Sep-06-23 08:00AM	ALX Oncology Realigns Executive Leadership Team (GlobeNewswire) +6.37%
Aug-31-23 07:00AM	ALX Oncology Announces September Investor Conference Participation (GlobeNewswire)
Aug-14-23 07:31PM	While dollars continue to flow into biotech, companies cut more jobs (American City Business Journals)
Aug-10-23 04:01PM	ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update (GlobeNewswire)
09:55AM	ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jun-26-23 07:00AM	ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer (GlobeNewswire)
May-11-23 04:01PM	ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
May-09-23 07:00AM	ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer (GlobeNewswire) +6.36%
Apr-25-23 07:00AM	ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma (GlobeNewswire)
Apr-19-23 11:36AM	These 2 Strong Buy Penny Stocks Could Rally to $40 (or More), Says Piper Sandler (TipRanks) +6.44%
Mar-14-23 08:00AM	ALX Oncology and Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer (PR Newswire) -6.75%
Mar-13-23 07:00AM	ALX Oncology and Quantum Leap Healthcare Collaborative Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer (GlobeNewswire)
Mar-09-23 04:01PM	ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones (GlobeNewswire) -5.93% -8.18%
Feb-16-23 07:00AM	ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer (GlobeNewswire)
Jan-05-23 07:00AM	ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023 (GlobeNewswire)
Jan-03-23 07:00AM	ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-22 10:00AM	ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia (GlobeNewswire) +5.12%
Nov-29-22 07:00AM	ALX Oncology Appoints Scott Garland to its Board of Directors (GlobeNewswire) +7.25%
Nov-08-22 04:01PM	ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
Nov-03-22 09:00AM	ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting (GlobeNewswire)
Nov-02-22 07:00AM	ALX Oncology Announces Upcoming Investor Conference Participation (GlobeNewswire)
Oct-31-22 07:00AM	ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept (GlobeNewswire)
Oct-05-22 08:01AM	ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (GlobeNewswire)
Sep-21-22 04:01PM	ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference (GlobeNewswire)
Sep-01-22 07:00AM	ALX Oncology Announces Upcoming Investor Conference Participation (GlobeNewswire)
Aug-16-22 09:45AM	ALX Oncology and Quantum Leap Healthcare Collaborative Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer (PR Newswire)
Aug-15-22 07:00AM	ALX Oncology and Quantum Leap Healthcare Collaborative Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer (GlobeNewswire)
Aug-11-22 07:00AM	ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer (GlobeNewswire)
Aug-08-22 04:01PM	ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (GlobeNewswire)
Aug-01-22 07:00AM	ALX Oncologys Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Jun-29-22 08:44AM	ALX's stock is up 11% after getting orphan-drug designation for cancer drug (MarketWatch)
07:00AM	ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia (GlobeNewswire)
Jun-22-22 09:00AM	Biora Therapeutics Announces Presentation at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference (GlobeNewswire)
Jun-03-22 07:00AM	ALX Oncology Announces Evorpacept Clinical Program Updates (GlobeNewswire)
Jun-01-22 07:00AM	ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference (GlobeNewswire)
Apr-12-22 07:00AM	ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors (GlobeNewswire)
Mar-02-22 07:00AM	ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer (GlobeNewswire)
Feb-28-22 07:00AM	ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones (GlobeNewswire) +7.54%
Feb-03-22 07:01PM	3 Strong Buy Small-Cap Stocks That Are Too Cheap to Ignore (TipRanks) -5.08%
Feb-02-22 01:38PM	HC Advisors, LLC Buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, ... (GuruFocus.com) -11.83%
Jan-28-22 12:44PM	ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC (Zacks) +5.85%
08:02AM	ALX Oncology's Evorpacept Gets Orphan Drug Tag For Gastric Cancer (Benzinga)
Jan-27-22 05:51PM	ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer (GlobeNewswire)
Jan-19-22 06:23AM	New Strong Sell Stocks for January 19th (Zacks)
Jan-10-22 06:00AM	ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022 (GlobeNewswire)
Jan-04-22 07:00AM	ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.62%
Dec-14-21 09:00AM	DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia (PR Newswire)

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hemrajani Rekha	Director	Dec 02 '24	Buy	1.55	30,000	46,404	33,000	Dec 04 04:17 PM
Pinto Shelly	SVP, FINANCE AND CAO	Aug 14 '24	Sale	2.58	564	1,455	91,549	Aug 16 05:10 PM
Randolph Sophia	CHIEF MEDICAL OFFICER	Aug 14 '24	Sale	2.58	1,365	3,522	325,711	Aug 16 05:09 PM
Pons Jaume	PRESIDENT & CSO	Aug 14 '24	Sale	2.58	1,937	4,997	591,510	Aug 16 05:06 PM
Pons Jaume	PRESIDENT & CSO	Jul 11 '24	Option Exercise	0.99	20,000	19,800	613,447	Jul 15 04:06 PM
Pons Jaume	PRESIDENT & CSO	Jul 11 '24	Sale	7.90	20,000	158,076	593,447	Jul 15 04:06 PM
Pinto Shelly	SVP, FINANCE AND CAO	Jul 05 '24	Sale	5.50	1,823	10,025	92,113	Jul 09 04:09 PM
Pinto Shelly	SVP, FINANCE AND CAO	Jul 01 '24	Sale	5.82	1,373	7,989	93,936	Jul 03 05:03 PM
Randolph Sophia	CHIEF MEDICAL OFFICER	Jul 01 '24	Sale	5.82	3,273	19,045	327,076	Jul 03 05:02 PM
Pons Jaume	PRESIDENT & CSO	Jul 01 '24	Sale	5.82	10,758	62,599	593,447	Jul 03 05:00 PM
GARCIA PETER S	CHIEF FINANCIAL OFFICER	Jun 13 '24	Buy	8.53	12,000	102,338	122,348	Jun 17 07:29 AM
Pons Jaume	PRESIDENT & CSO	Jun 04 '24	Option Exercise	0.99	20,000	19,800	624,205	Jun 06 04:06 PM
Pons Jaume	PRESIDENT & CSO	Jun 04 '24	Sale	8.43	20,000	168,652	604,205	Jun 06 04:06 PM
Randolph Sophia	CHIEF MEDICAL OFFICER	May 13 '24	Sale	15.94	12,000	191,339	330,349	May 15 04:30 PM
Pons Jaume	PRESIDENT & CSO	May 06 '24	Option Exercise	0.99	20,000	19,800	624,205	May 08 05:31 PM
Pons Jaume	PRESIDENT & CSO	May 06 '24	Sale	15.92	20,000	318,334	604,205	May 08 05:31 PM
Pons Jaume	PRESIDENT & CSO	Apr 16 '24	Option Exercise	0.99	25,846	25,588	654,205	Apr 18 04:49 PM
Pons Jaume	PRESIDENT & CSO	Apr 16 '24	Sale	14.20	50,000	710,195	604,205	Apr 18 04:49 PM
Pons Jaume	PRESIDENT & CSO	Apr 04 '24	Sale	11.15	20,000	223,036	628,359	Apr 05 05:37 PM
Lettmann Jason	CHIEF EXECUTIVE OFFICER	Mar 14 '24	Buy	11.31	4,400	49,771	171,620	Mar 18 04:06 PM
Pinto Shelly	SVP, Finance and CAO	Jan 04 '24	Sale	13.60	2,717	36,957	78,591	Jan 05 04:03 PM
Pinto Shelly	SVP, Finance and CAO	Dec 29 '23	Sale	15.04	1,631	24,530	81,308	Jan 03 04:28 PM
Randolph Sophia	Chief Medical Officer	Dec 29 '23	Sale	15.04	3,128	47,045	312,349	Jan 03 04:25 PM
GARCIA PETER S	Chief Financial Officer	Dec 29 '23	Sale	15.04	1,893	28,471	85,348	Jan 03 04:20 PM
Pons Jaume	President & CSO	Dec 29 '23	Sale	15.04	7,179	107,972	618,359	Jan 03 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALXO

Alx Oncology Holdings Inc

Upgrade your FINVIZ experience